^
Association details:
| Biomarker: | KIT mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide capsule) (Androgen receptor inhibitor) + abiraterone acetate (CYP17A1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Comparison of ctDNA between African American and Caucasian patients with CRPC post abiraterone and/or enzalutamide.
Published date:
02/13/2023
Excerpt:
African Americans with CRPC post treatment with abiraterone and/or enzalutamide had a higher frequency of P/LP CDK12 and KIT mutations, which have both been shown to lead to aggressive clinical features and treatment resistance.
DOI:
10.1200/JCO.2023.41.6_suppl.35
